Background: Respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI)
| INTRODUC TI ON
Infection with respiratory syncytial virus (RSV) is a major cause of death in in immunocompromised patients with hematologic malignancies (HM) with or without hematopoietic cell transplantation (HCT). 1, 2 The incidence of infection is estimated between 2%-17% in HCT recipients, 3 and mortality rates after lower respiratory tract infection (LRTI) can reach up to 80%. [4] [5] [6] New therapies and strategies are needed to improve outcomes after RSV LRTI in immunocompromised hosts.
Once an RSV diagnosis is confirmed, risk stratification in HM patients is critical given the high cost of therapy with aerosolized ribavirin 7 and high mortality rates after LRTI. 3, 5, [8] [9] [10] [11] Prior studies have identified lymphopenia, neutropenia, and RSV detection in lower respiratory samples as important risk factors for mortality after LRTI. 8, [11] [12] [13] Recognition of individuals at high risk for adverse outcomes could improve the prompt delivery of ribavirin treatment, which may reduce mortality and morbidity. 9 We previously developed an immunodeficiency scoring index based on clinical characteristics and laboratory parameters to standardize the risk stratification practices of allogeneic HCT (allo-HCT) recipients with RSV upper respiratory tract infection (URTI), a group at high risk for adverse outcomes after RSV Infection. 13, 14 We hypothesized that among HM patients without HCT and those who are autologous HCT (auto-HCT) or allo-HCT recipients, allo-HCT recipients would be at the highest risk for mortality. We further hypothesized that isolation of RSV and other respiratory pathogens from the lower respiratory tract among patients who underwent fiberoptic bronchoscopy would be associated with higher mortality, as demonstrated in parainfluenza viral infection. 15 We also sought to determine whether more severe immunodeficiency in HCT recipients, as determined by the Immunodeficiency Score Index (ISI) 13, 16 and the severe immunodeficiency (SID) criteria, 17, 18 predicted mortality after RSV LRTI.
| MATERIAL S AND ME THODS

| Study design
We conducted a retrospective review of all adults with any type of leukemia or lymphoma or multiple myeloma (HM), some of whom underwent auto-or allo-HCT, and who were 18 years of age or older with an RSV infection cared for at The University of Texas MD Anderson Cancer Center from 01/96 to 07/13. Patients were identified from a prospectively-maintained infection control database of viral infections. We collected data on patients' demographics, underlying malignancy, immune status at diagnosis, antiviral therapy, thoracic imaging and microbiologic data. We also collected data on outcomes including hospital admission, intensive care unit (ICU) admission, mechanical ventilation, and all-cause mortality at days 30 and 60. This study was approved by our Institutional Review Board (DR09-0696 and PA12-0483) in accordance with the Helsinki Declaration of the World Medical Association, and waiver of informed consent was granted. 
| Definitions
| Clinical evaluation of RSV infection
Radiographic images were independently reviewed by two pulmonologists (E.V. and A.S.) and discrepancies were resolved by mutual agreement. We excluded patients who had resolving infiltrates from a known prior LRTI and those with clinical volume overload as assessed by echocardiography, right heart catheterization, or response to diuretics. Prior to 2001, 19 patients did not have images available for independent review. In those cases, the radiologist's interpretation, as documented in the medical record, was used. Bronchoscopy was performed in a dedicated endoscopy suite under the supervision of an experienced pulmonologist.
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The results from bronchial washing were excluded to minimize contamination from the upper respiratory tract. For patients with possible RSV LRTI who did not undergo bronchoscopy (n = 93), the reason for not performing bronchoscopy was recorded when available (Table S1 ).
| Grading of immunodeficiency in HCT recipients
All HCT recipients were scored using ISI and SID criteria at the time of RSV LRTI. ISI ranges from 0-12, and ISI scores were calculated as previously described with 3 points given each for ANC < 
| Statistical analysis
Descriptive statistics were calculated for demographic, clinical, and therapeutic data. Categorical variables were compared using chi-square or Fisher's exact test and continuous variables were compared using one-way analysis of variance. Multivariable logistic regression analyses were performed to identify independent risk factors associated with 60-day all-cause mortality. All patients were followed for the entire 60 days, and outcomes were right-censored after 60-days. All variables were entered into the multivariable model, and backward elimination was used to only include variables 
| RE SULTS
| Clinical characteristics and outcomes of patients with possible and proven RSV LRTI
We identified 154 patients who met our inclusion and exclusion criteria, 61 (40%) of whom underwent bronchoscopy with BAL (Table 1) .
Median age was 54 years (range 18-79 years) and 65 (42%) were female. There were 69 (45%) patients without HCT, 28 (18%) with auto-HCT and 58 (38%) with allo-HCT. Possible RSV LRTI was diagnosed in 131 (85%) patients and proven RSV LRTI in 23 (15%) patients. Allo-HCT recipients were younger, and auto-HCT recipients were more likely to have multiple myeloma as an underlying malignancy and to be on corticosteroids. Among HCT recipients, the median time between HCT and LRTI was 215 days (interquartile range: 58-693 days).
Patients without HCT were more likely to receive chemotherapy within 1 month of RSV LRTI and have neutropenia or lymphopenia, but were less likely to receive ribavirin therapy. RSV alone was detected in 18 (30%) of the 63 BAL samples, RSV with concurrent non-RSV respiratory pathogens was detected in 5 (8%), non-RSV pathogens alone were detected in 12 (20%), and no pathogens were detected in 26 (43%). The majority of patients who did not undergo bronchoscopy (82 of 93) were not referred for the procedure at the discretion of their primary oncologist or transplant physician (Table S1 ).
| Outcomes after RSV LRTI
Hospitalization at the time of RSV was common among patients in our cohort (61%), although patients without HCT were less likely to be hospitalized ( Table 2 ). There were no differences in rates of ICU admission, mechanical ventilation, 30-day mortality, or 60-day mortality between patients without HCT, allo-HCT recipients, and auto-HCT recipients, and 60-day mortality was high across all groups (39/154, 25%). Patients with proven LRTI were more likely to be admitted to the ICU (48% vs 31%, P = 0.03), and to die at 30 days (36% vs 14%, P = 0.03) and 60 days (52% vs 21%, P = 0.003) after LRTI onset (Table 3 ).
| Predictors of mortality after RSV LRTI
In univariate logistic regression models, neutropenia at RSV diag- ALC, absolute lymphocyte count; ANC, absolute neutrophil count; BAL, bronchoalveolar lavage; HCT, hematopoietic cell transplant; HM, hematologic malignancy; LRTI, lower respiratory tract infection; RSV, respiratory syncytial virus; URTI, upper respiratory tract infection. Allo-HCT recipients were younger, and auto-HCT recipients were more likely to have multiple myeloma as an underlying malignancy and to be on corticosteroids. Patients without HCT were more likely to receive chemotherapy within 1 month of RSV LRTI and have neutropenia or lymphopenia, but were less likely to receive ribavirin therapy (in bold).
Kaplan-Meier survival curves are shown for patients with HM but no HCT, allo-HCT recipients, and auto-HCT recipients in Figure 1 . There was no significant difference in survival between those groups (P = 0.63). Kaplan-Meier curves demonstrated that patients with proven LRTI had lower survival rates than those with possible LRTI (P < 0.001, Figure 2 ). Sub-group analyses revealed that there were significant differences between the survival curves of pa- 
| Effect of immunodeficiency on mortality in HCT recipients with RSV LRTI
We calculated ISI grade and SID criteria for 85 HCT recipients and measured association with mortality. High-risk individuals as identified by ISI had a higher risk for mortality than low-risk individuals (OR 10.5, 95% CI 1.9-56.6, P = 0.01, Table 5 
| D ISCUSS I ON
We observed high mortality after RSV LRTI in HM patients, with or without HCT. However, there was no difference in 60-day mortality between HM patients without HCT, allo-HCT and auto-HCT recipients. Lymphopenia and neutropenia were independent predictors of 60-day mortality. Furthermore, detection of RSV from BAL fluid, defined as proven RSV LRTI was associated with higher all-cause mortality at 30 and 60 days and a higher rate of ICU admission. High-grade immunodeficiency, as defined by ISI grade and SID criteria, was associated with higher rates of 60-day all-cause mortality.
Consistent with other studies of viral LRTI, we found that mortality in HM patients, with or without HCT, was high. Our mortality rate of 25% across groups is similar to other studies of HM patients with RSV LRTI. In patients with acute myeloid leukemia at our institution, 5/27 (19%) patients with RSV LRTI died. 9 In contemporary cohorts of HCT recipients with RSV LRTI, the overall mortality ranged from 11%-30%. 3, 5, 8, 10, 11 Allo-HCT recipients often have high-risk underlying malignancies and require immunosuppression as compared to auto-HCT recipients.
14 However, we found that mortality was high in all HM patients regardless of HCT status. This is similar to other groups who have found no difference in the risk for mortality be- While it is possible that allo-HCT recipients are at a higher risk for death after adjusting for the presence of neutropenia, our study cannot definitively prove this.
Previous studies showed that neutropenia 8, 13 and lymphopenia 8,12,13 are associated with a higher risk of death in HCT recipients with RSV LRTI. In separate multivariate models, we found that 
TA B L E 5 Impact of immunodeficiency on 60-d mortality after RSV LRTI in HCT recipients
lymphopenia and neutropenia were associated with 60-day mortality. Lymphopenia is associated with increased progression from URTI to LRTI, 13,23 a well-known marker of mortality. 17, 24 Similarly, neutropenia is independently associated with progression to RSV LRTI. 13 Conversely, normal lymphocyte counts are associated with low rates of progression to LRTI. 23 Furthermore, we found that high-grade immunodeficiency, as defined by ISI and SID criteria, was highly-associated with mortality. Whether using ISI or SID criteria, high-grade immunodeficiency was associated with a 60-day all-cause mortality around 50% after RSV LRTI, which is similar to prior studies. The initial development cohort for ISI consisted of 237 allo-HCT recipients with RSV LRTI or URTI 13 and mortality was high among those who did not receive ribavirin at the URTI stage and progressed to LRTI (63% at 90 days) and among those who presented with an LRTI and received ribavirin at diagnosis (50% at 90 days).
Importantly, the ISI was developed in a cohort of allo-HCT recipients and was designed to predict progression from RSV URTI to LRTI. As our current study shows, ISI is less useful in auto-HCT recipients, particularly since certain criteria such as graft-versus-host disease may not be applicable. Similarly, a study of 45 patients with RSV LRTI found that high-risk patients, as identified by ISI, had a RSVassociated mortality of 50%. 16 High ISI is also associated with high mortality after influenza infection. 25 SID criteria were first studied in 34 patients with RSV infection, of whom 18% died. 17 Risk factors for mortality included LRTI, pre-engraftment status and vSID at RSV diagnosis. A recent study of SID criteria in 66 patients with RSV, PIV, and hMPV infection showed a mortality of 32% in patients with vSID, and no deaths in patients with MID or SID. Our findings are consistent with prior studies that show that immunocompromised patients are at high risk for mortality after RSV infection.
8,16-18
In agreement with other studies, 8, 26 we did not find an association between corticosteroid use at the time of LRTI and mortality.
Corticosteroid use was used as part of the Immunodeficiency Scoring Index, a tool to predict the risk of progression from RSV URTI to LRTI in allo-HCT recipients, but was not independently associated with progression to RSV LRTI. 13 However, in a mixed cohort of patients with hMPV and RSV LRTI, corticosteroid use and hypoxemia were associated with increased mortality. 22 Similarly, corticosteroid use at the diagnosis of RSV infection is associated with a higher incidence of hypoxemia in a dose-dependent fashion. 11 Future prospective studies are necessary to investigate the timing and dosage of corticosteroid administration and its relationship with mortality after RSV LRTI.
High-risk HM patients with RSV infection, particularly HCT recipients, should be considered as candidates for ribavirin therapy at the URTI stage, as early treatment may prevent LRTI. 9 We did not find a significant difference in mortality in patients who started ribavirin therapy when it was given at the LRTI stage, but our study was not designed to investigate the efficacy of ribavirin. Furthermore, ribavirin given at the LRTI stage can still be beneficial in some instances, as demonstrated in few studies. 8, 10, 27, 28 Despite the lack of statistical significance, there was a trend toward a protective effect of ribavirin for mortality in our cohort when given at the URTI stage in patients who eventually developed RSV LRTI. Future prospective studies are necessary to validate the optimal route (oral or aerosolized) and timing (URTI or LRTI) of ribavirin therapy.
Some groups define patients as having LRTI when RSV is detected in the upper respiratory tract and there are lower respiratory tract symptoms or new pulmonary infiltrates. There are several limitations to our findings. This is a retrospective cohort analysis, and our findings require further confirmation in prospective studies. Not all patients were referred for bronchoscopy, so those with possible RSV LRTI may have been less sick, resulting in a referral bias. However, if patients were not referred because they were too sick to undergo bronchoscopy, this would bias our results towards the null hypothesis. We used viral Associations of ISI with mortality in auto-HCT recipients should be interpreted with caution, since ISI was not developed to quantify immunodeficiency in auto-HCT recipients. Because of the small size of the cohort and the small number of deaths (n = 39), we could not measure the interaction of proven RSV LRTI with immunodeficiency scoring, and our findings need to be replicated in a larger, prospective cohort.
In conclusion, we found that mortality was high in HM patients, with or without HCT, who developed RSV LRTI. Neutropenia and lymphopenia were predictive of 60-day mortality. In addition, highrisk ISI or vSID at RSV diagnosis were associated with higher 60-day mortality. Furthermore, detection of RSV in BAL fluid was associated with higher 60-day all-cause mortality than in those without RSV detected in BAL. Routine calculation of immunodeficiency scores may improve risk stratification in HCT recipients. Data from BAL may complement these immunodeficiency scores 13, [16] [17] [18] 25 and be useful for identifying patients with RSV infection or other respiratory viruses who are at the greatest risk for death. Such patients would be ideal candidates for early ribavirin therapy or for clinical trials for new investigational drugs.
